← All trials
NCT05794555
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 13, 2023
- Primary completion
- May 31, 2025
- Completion date
- Sep 30, 2025
- First posted
- Apr 3, 2023
- Last posted
- Sep 11, 2023
- Enrollment
- 215
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MichiganLead sponsor
- University of PennsylvaniaOverall official - principal investigator
- University of MichiganOverall official - principal investigator
- University of MichiganReponsible party - principal investigator
- Patient-Centered Outcomes Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.